Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV003301191 | SCV004001151 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-04-01 | criteria provided, single submitter | clinical testing | The p.F64L variant (also known as c.192C>G), located in coding exon 3 of the RAD51D gene, results from a C to G substitution at nucleotide position 192. The phenylalanine at codon 64 is replaced by leucine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |